Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.

Author: BessesCarlos, BirgegårdGunnar, CollRuth, GriesshammerMartin, GugliottaLuigi, HarrisonClaire, KiladjianJean-Jacques, SmithJonathan

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Hydroxycarbamide was the most frequently prescribed cytoreductive therapy for very elderly patients with essential thrombocythaemia, with a median platelet count of ~430 × 10(9)/L.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The median age of patients diagnosed with essential thrombocythaemia (ET) is 65-70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized. OBJECTIVE: This study aimed to document the treatment patterns of very elderly patients with ET ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586170/

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Essential Thrombocythaemia

Essential Thrombocythaemia (ET) is a complex condition, like a desert landscape with ever-changing dunes. This study focuses on the management of very elderly patients (aged >80 years) with ET, a group often overlooked in research. The study is like an archaeological dig, unearthing real-world treatment patterns and revealing how cytoreductive therapies are used in this population.

A Detailed Map of Treatment

The researchers, acting as skilled cartographers, created a map of treatment patterns for very elderly ET patients in a multinational setting. They found that hydroxycarbamide (HC) was the most frequently prescribed cytoreductive therapy, while anagrelide use was less common. They also discovered that very elderly patients were more likely to switch from anagrelide than from HC. This suggests that these two therapies might have different tolerability profiles in this population.

A Guide to Effective Management

This study provides valuable insights into the management of ET in the very elderly, a group that often faces unique challenges. It highlights the importance of personalized treatment plans tailored to individual needs and preferences, like navigating a desert with a customized map. This study is a crucial step towards improving the care of very elderly patients with ET.

Dr.Camel's Conclusion

This study provides valuable insights into the management of ET in the very elderly, highlighting the importance of personalized treatment plans tailored to individual needs and preferences, like navigating a desert with a customized map. This study is a crucial step towards improving the care of very elderly patients with ET.

Date :
  1. Date Completed 2013-07-02
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23184668

DOI: Digital Object Identifier

PMC3586170

Related Literature

Article Analysis
・Effects of anagrelide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.